Emerging evidence demonstrates that an increasing number of novel medications have considerable potential to induce adrenal insufficiency. This condition might lead to acute adrenocortical insufficiency, which is potentially fatal; however, the condition could be avoided if clinicians are more aware of the new findings and their implications.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Adrenal hypofunction associated with ashwagandha (Withania somnifera) supplementation: a case report
Toxicology and Environmental Health Sciences Open Access 14 February 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bornstein, S. R. Predisposing factors for adrenal insufficiency. N. Engl. J. Med. 360, 2328–2339 (2009).
Bornstein, S. R. et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab 101, 364–389 (2016).
Mebrahtu, T. F. et al. Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/jc.2019-00153 (2019).
Ferraldeschi, R. et al. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin. Cancer Res. 19, 3353–3359 (2013).
Oksala, R. et al. SUN-LB002 CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer. J. Endocr. Soc. https://doi.org/10.1210/js.2019-SUN-LB002 (2019).
Hofmann, A. et al. Aldosterone synthase inhibition improves glucose tolerance in zucker diabetic fatty (ZDF) rats. Endocrinology 157, 3844–3855 (2016).
Tan, M. H. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diabetes Endocrinol. 5, 1 (2019).
Gupta, S. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vasc. Health Risk Manag. 12, 421–433 (2016).
Donegan, D. Opioid induced adrenal insufficiency: what is new? Curr. Opin. Endocrinol. Diabetes Obes. 26, 133–138 (2019).
Harvey, P. W. Adrenocortical endocrine disruption. J. Steroid Biochem. Mol. Biol. 155, 199–206 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bornstein, S.R., Bornstein, T.D. & Andoniadou, C.L. Novel medications inducing adrenal insufficiency. Nat Rev Endocrinol 15, 561–562 (2019). https://doi.org/10.1038/s41574-019-0248-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0248-9
This article is cited by
-
Adrenal hypofunction associated with ashwagandha (Withania somnifera) supplementation: a case report
Toxicology and Environmental Health Sciences (2022)
-
Adrenal insufficiency
Nature Reviews Disease Primers (2021)
-
Consequences of the COVID-19 pandemic for patients with metabolic diseases
Nature Metabolism (2021)